Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Advanced Cancers × Sorafenib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Hepatocellular 121 Liver Neoplasms 38 Leukemia, Myeloid, Acute 32 Carcinoma, Renal Cell 32 Neoplasm Metastasis 24 Breast Neoplasms 23 Carcinoma, Non-Small-Cell Lung 20 Kidney Neoplasms 16 Pancreatic Neoplasms 12 Neoplasms 12 Prostatic Neoplasms 11 Lung Neoplasms 11 Sarcoma 9 Recurrence 9 Melanoma 9 Myelodysplastic Syndromes 8 Colorectal Neoplasms 8 Brain Neoplasms 8 Precursor Cell Lymphoblastic Leukemia-Lymphoma 6 Leukemia 6 Glioblastoma 6 Urinary Bladder Neoplasms 5 Multiple Myeloma 5 Leukemia, Myelomonocytic, Chronic 5 Thyroid Neoplasms 4 Stomach Neoplasms 4 Ovarian Neoplasms 4 Liver Diseases 4 Adenocarcinoma of Lung 4 Adenocarcinoma 4

Interventions

Surveys and Questionnaires 5 pazopanib 3 Erlotinib Hydrochloride 3 Cetuximab 3 Vorinostat 2 Oxaliplatin 2 Bevacizumab 2 Azacitidine 2 satraplatin 1 ixazomib 1 X-Rays 1 Videotape Recording 1 Valproic Acid 1 Trastuzumab 1 Sugars 1 Sorafenib 1 Platinum 1 Pemetrexed 1 Magnetic Resonance Spectroscopy 1 Leucovorin 1 Lenalidomide 1 Lapatinib 1 LY 2275796 1 Fluorouracil 1 Everolimus 1 Curcumin 1 Crizotinib 1 Capecitabine 1 Asian ginseng 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01608139 2012-10-19

Study of Curcumin, Vorinostat, and Sorafenib

M.D. Anderson Cancer Center

Phase 1 Withdrawn

Advanced Cancers

Data powered by HemOnc (CC BY 4.0) Colophon ⚡